The radioactive halogen astatine-211 was injected into mice in an amount producing minimal toxicity. Histopathological examination of tissues at intervals between 3 d and 16 weeks showed the following changes:
1 Radiation-induced necrosis and progressive fibrosis of the thyroid gland. The gland was reduced to 25% of its original mass with only a few relatively normal follicles persisting.
2 A small, temporary, reduction in peripheral blood lymphocytes, platelets and red cells and a significant persistant increase in polymorphs.
3 Severe reduction in reproductive cells in the testis with some signs of recovery at 16 weeks.
Get full access to this article
View all access options for this article.
References
1.
Hamilton JG , Durbin PW & Parrott MWComparison of acute and chronic changes produced in rats by iodine-131 and astatine-211 at lethal levels. Preliminary clinical data on the uptake of astatine-211 by patients with thyroid disease. Medical and Physiological Applications, Volume 1. Proceedings of the second conference, Oxford , 19-23 July, ed, JE Johnston, pp. 219-31, London: Butterworths Scientific Publications , 1954.
2.
2Cobb LM, Harrison A. & Butler SAToxicity of astatine-211 in the mouse. Human Toxicology1988; 7: 529-34.
3.
Cobb LM , Harrison A., Dudley NE, Carr Tef & Humphreys JARelative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice. Radiotherapy andOncology1989; 13: 203-9.
4.
Harrison A. & Royle L.Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. National Cancer Institute Monographs1987; 3: 157-8.
5.
Brown I.Astatine-211: Its possible applications in cancer therapy . Applied Radiation and Isotopes1986; 37: 789-98.
6.
Cobb LM & Humm JLRadioimmunotherapy of malignancy using antibody targeting radionuclides . British Journal of Cancer1986; 54: 863-70.
7.
Link EM , Brown I., Carpenter RN & Mitchell JSUptake and therapeutic effectiveness of 125I- and 211At-methylene blue for pigmented melanoma in an animal model system. Cancer Research1989; 49: 4332-7.
8.
Harrison A.The application of 211 At in experimental tumour therapy . Radiochimica Acta1989; 47: 157-61.
9.
Humm J.Dosimetric aspects of radiolabeled antibodies for tumor therapy . Journal of Nuclear Medicine1986; 27: 1490-7.
10.
Hamilton JG , Asling CW, Garrison WM et al. The accumulation, metabolism and biological effects of astatine in rats and monkeys. University of California Publications in Pharmacology1953; 2: 283-343.
11.
Jardine LJDecays of 211 At, 211Po and 207BiPhysical Review C 1975; 11: 1385-91.
12.
Sims HE211At and 90Y: two nuclides for potential use in tumour therapy - production at Harwell Laboratory, AERE, 1986, R 12209.
13.
Treilhou-Lahille F. , Cressent M., Taboulet J. & Moukhtar MSDémonstration immunohistochimique des cellules à calcitonine de la thyroïde foetale des Souris. Comptes Rendus Academie Sciences, Série D 1979 ; 289: 421-3.
14.
Feinstein RE , Gimeno EJ, El-Salhy M., Wilander E. & Walinder G.Evidence of C-cell destruction in the thyroid gland of mice exposed to high 131I doses . Acta Radiologica Oncology1986; 25: 199-202.
15.
Harrison A. & Royle L.Determination of absorbed dose to blood, kidneys, testes and thyroid in mice injected with 211At and comparison of testes mass and sperm numbers in X-irradiated and 211At treated mice. Health Physics1984 ; 46: 377-83.
16.
Handelsman DJ , Conway AJ, Donnelly PE et al. Azoospermia after Iodine-131 treatment for thyroid carcinoma. British Medical Journal1980; 281: 1527.
